A Non-interventional Cohort Safety Study of Patients With hATTR-PN
Recruiting
- Conditions
- Hereditary Transthyretin Amyloidosis With Polyneuropthy
- Interventions
- Other: Data Collection
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 240
- Registration Number
- NCT04850105
- Locations
- 🇪🇸
Study Centre, Madrid, Comunidad De Madrid, Spain
🇪🇸Study Center, Madrid, Spain
A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN
Phase 4
Terminated
- Conditions
- Hereditary Transthyretin Amyloidosis With Polyneuropthy
- Interventions
- Procedure: Blood samples for immunoglobulinsProcedure: Blood samples for inflammatory markersProcedure: Blood samples for anti-drug antibodies
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT04306510
- Locations
- 🇨🇦
Study Center, Toronto, Ontario, Canada
TEGSEDI Pregnancy Surveillance Program
Recruiting
- Conditions
- Hereditary Transthyretin-mediated Amyloidosis With PolyneropathyPregnancy
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04270058
- Locations
- 🇺🇸
TEGSEDI Pregnancy Coordinating Center, Morgantown, West Virginia, United States
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Familial Chylomicronemia
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Akcea Therapeutics
- Registration Number
- NCT03544060
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT03514420
- Locations
- 🇺🇸
Clinical Site, Ann Arbor, Michigan, United States
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT03506854
- Locations
- 🇨🇦
Clinical Site, Québec, Canada
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2
Withdrawn
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Akcea Therapeutics
- Registration Number
- NCT03455777
- Locations
- 🇨🇦
Clinical Site, Québec, Quebec, Canada
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
Phase 1
Completed
- Conditions
- Elevated Lipoprotein(a)Cardiovascular Diseases
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03426033
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
Phase 1
Completed
- Conditions
- Elevated Lipoprotein(a)Cardiovascular Diseases
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03392051
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
Phase 2
Completed
- Conditions
- HypertriglyceridemiaCardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 114
- Registration Number
- NCT03385239
- Locations
- 🇨🇦
Clinical Site, Québec, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath